Clinical Trials Logo

Filter by:
NCT ID: NCT05505617 Recruiting - Systemic Sclerosis Clinical Trials

Nitric Oxide Lung Diffusing Capacity in Systemic Sclerosis

Start date: October 17, 2022
Phase:
Study type: Observational

To date, two devices to measure nitric oxide lung diffusing capacity (DLNO) are commercially available in Europe. Previous research has shown systematic between-device differences in lung diffusing capacity outcomes in healthy people (Radtke et al. ERJ Open Res. 2021 Sep 13;7(3)). The extent and magnitude of between-device differences in people with lung function impairment and ventilation inhomogeneities is unknown.

NCT ID: NCT05505058 Completed - Informed Consent Clinical Trials

One-time Informed Consent for Research in Prison

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

Ethical research on detained persons remains limited, including research on informed consent. This study aimed to fill in this research gap and compared audio-visual and paper-based materials for a one-time general informed consent for research in prison, using a randomized design. The primary outcome was whether participants sign the inform consent. Secondary outcomes included understanding, evaluation, and time to read/watch the informed consent.

NCT ID: NCT05504941 Recruiting - Clinical trials for Intracerebral Hemorrhage

Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage

HemEXPLO
Start date: October 25, 2022
Phase: N/A
Study type: Interventional

This study is to determine if a treatment target for a potential endovascular therapy exists in patients with an acute, spontaneous (non-traumatic) ICH.

NCT ID: NCT05504473 Completed - Facial Nerve Palsy Clinical Trials

Blink Restoration in Patients With Facial Nerve Palsy

NEURO-BLINK
Start date: March 31, 2022
Phase: N/A
Study type: Interventional

This study is a non-blinded single armed pilot study aiming to apply a newly created medical device in patients with seventh nerve palsy suffering from lagophthalmus in order to determine the best way for neuromuscular stimulation of the orbicularis oculi muscle and facial nerve in order to enable eyelid closure (blink). Initially, a tailored external neurostimulation prototype will be created in collaboration with the ETH for patients with facial nerve palsy and lagophthalmos. Aim of this study is to create an efficient, safe and comfortable medical device that can achieve an effective blinking through external electrical neuromuscular stimulation of the orbicularis oculi in patients with facial palsy and lagophthalmos. Such a device can become an essential part of facial palsy treatment.

NCT ID: NCT05503212 Completed - Ischemic Stroke Clinical Trials

Best Revascularisation Approach for Posterior Circulation Strokes With Isolated Vertebral Artery Occlusions

BRAVO
Start date: January 1, 2003
Phase:
Study type: Observational

Isolated vertebral artery occlusions (VAO) account for approximately one third of posterior circulation occlusions, but have been given the least attention among posterior circulation strokes. If the two recent ATTENTION and BAOCHE randomized clinical trials have proven the superiority of endovascular thrombectomy (EVT) in basilar artery occlusions, data on the effectiveness and harm of acute revascularization treatment on isolated VAO is scarce. We aim to investigate the impact of acute recanalisation treatments in acute ischemic stroke patients with isolated VAO. In the absence of RCT, observational data with appropriate statistical methods may give indications on benefits and harms of treating neglected stroke situations like acute vertebral occlusion. Results may also lay the basis for prospective studies, such as randomized clinical trials.

NCT ID: NCT05502380 Recruiting - Clinical trials for Surgical Site Infection

Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery

BAPTIST
Start date: September 15, 2022
Phase: Phase 3
Study type: Interventional

The perioperative antibiotic prophylaxis is evidence-based in orthopedic surgery. While its duration ranges from a single dose to three doses throughout the world, the choice of the prophylactic agents is undisputed. Worldwide, the surgeons use 1st or 2nd-generation cephalosporins (or vancomycin in some cases). However, there are particular clinical situation with a high risk of antibiotic-resistant surgical site infections (SSI); independently of the duration of adminis-tered prophylaxis. These resistant SSI's occur in contaminated wounds, or during surgery under current therapeutic antibiotics, and base on "selection" by antibiotics used for therapy or for prophylaxis.

NCT ID: NCT05500859 Recruiting - Clinical trials for Cardiovascular Diseases (CVD)

Swiss Secondary Prevention and Rehabilitation Registry

SwissPR
Start date: December 20, 2019
Phase:
Study type: Observational [Patient Registry]

The SwissPR study is to continuously monitor patient characteristics and short- and long-term benchmark quality measures and outcomes of patients participating in a 12-week ambulatory CR program.

NCT ID: NCT05499832 Recruiting - Ischemic Stroke Clinical Trials

Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

TECNO
Start date: March 21, 2023
Phase: Phase 3
Study type: Interventional

TECNO is a multicenter, prospective, randomized, open label, blinded endpoint (PROBE) proof-of-concept trial evaluating if additional administration of intra-arterial Tenecteplase (TNK) improves reperfusion in patients with incomplete mechanical thrombectomy (MT). For this purpose, 156 adult participants experiencing an acute ischemic stroke due to a large vessel occlusion with incomplete reperfusion with residual occlusions after MT will be randomly assigned to receive 3mg intra-arterial (IA) TNK or best medical treatment. Recruitment will occur at 20 academic tertiary stroke care centers in Switzerland, Spain, Belgium, and Germany and patients are followed up for 90 days after the index event. Showing superiority for reperfusion outcomes would have a major impact on the future management of stroke patients.

NCT ID: NCT05499637 Recruiting - Cardiac Sarcoidosis Clinical Trials

[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

Start date: January 17, 2023
Phase: Phase 2
Study type: Interventional

Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging. Since accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of [68Ga]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients. The identification of a correlation between [68Ga]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.

NCT ID: NCT05499481 Recruiting - Clinical trials for Antibiotic Side Effect

Short Against Long Antibiotic Therapy for Infected Orthopedic Sites

SALATIO
Start date: September 15, 2022
Phase: Phase 3
Study type: Interventional

The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment: - SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy. - SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.